Pharma and charities in the UK gave a lukewarm welcome to the formal launch of the revamped Cancer Drugs Fund, saying the new entity – controlled by the National Institute For Health and Clinical Excellence (NICE) – will not solve underlying problems of drug reimbursement which, in turn, restrict access to novel oncology therapies.
NHS England earlier in July issued new guidelines on how cancer drugs will be appraised and funded in the UK, including the operation of the controversial Cancer Drugs Fund (CDF), which had been established in 2011 as a separate silo fund for cancer drugs that NICE assessed as being too costly for the publicly funded National Health Service (NHS). It was closed in March after heavily overspending
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?